Evidence that Fas and FasL Contribute to the Pathogenesis of Experimental Autoimmune Encephalomyelitis

Archivum Immunologiae et Therapiae Experimentalis

Volumn 48, Issue 5, 2000, Pages 381-388

  Dittel, Bonnie N ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

Experimental autoimmune encephalomyelitis; Fas; Fas ligand

Indexed keywords

FAS ANTIGEN; FAS LIGAND; FASL PROTEIN, MOUSE; FASLG PROTEIN, HUMAN; MEMBRANE PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; BIOLOGICAL MODEL; CYTOTOXICITY; REVIEW;

ANTIGENS, CD95; CYTOTOXICITY, IMMUNOLOGIC; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FAS LIGAND PROTEIN; MEMBRANE GLYCOPROTEINS; MODELS, IMMUNOLOGICAL;

EID: 0041903740     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. + lymphocytes delete activated macrophages through the Fas/APO-1 antigen pathway. Proc. Natl. Acad. Sci. USA, 92, 11225-11229.
2. BARON J. L., MADRI J. A., RUDDLE N. H., HASHIM G. and JANEWAY C. A. JR. (1993): Surface expression of α4 integrin by CD4 T cells is required for their entry into brain parenchyma. J. Exp. Med., 177, 57-68.
3. BOGDAN C. (1998): The multiplex function of nitric oxide in (auto)immunity. J. Exp. Med., 187, 1361-1365.
4. BRUNNER T., MOGIL R. J., LA FACE D., YOO N. J., MAHBOUBI A., ECHEVERRI F., MARTIN S. J., FORCE W. R., LYNCH D. H., WARE C. F. and GREEN D. R. (1995): Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature, 373, 441-444.
5. CLEMENT M.-V. and STAMENKOVIC I. (1994): Fas and tumor necrosis factor receptor-mediated cell death: similarities and distinctions. J. Exp. Med., 180, 557-567.
6. CHU J. L., RAMOS P., ROSENDORFF A., NIKOLIC-ZUGIC J., LACY E., MATSUZAWA A. and ELDON K. B. (1995): Massive upregulation of the Fas ligand in lpr and gld mice: implications for Fas regulation and the graft-versus-host disease-like wasting syndrome. J. Exp. Med., 181, 393-398.
7. CUA D. J., HINTON D. R. and STOHLMAN S. A. (1995): Self-antigen-induced Th2 responses in experimental allergic encephalomyelitis (EAE)-resistant mice. Th2-mediated suppression of autoimmune disease. J. Immunol., 155, 4052-4059.
8. DHEIN J., WALCZAK H., BAUMLER C., DEBATIN K.-M. and KRAMMER P. H. (1995): Autocrine T-cell suicide mediated by APO-1/(FAS/CD95). Nature, 373, 438-441.
9. DITTEL B. N., MERCHANT R. M. and JANEWAY C. A. JR. (1999): Evidence for Fas-dependent and Fas-independent mechanisms in the pathogenesis of experimental autoimmune encephalomyelitis. J. Immunol., 162, 6392-6400.
10. DITTEL B. N., SANT ANGELO D. B. and JANEWAY C. A. JR. (1997): Peptide antagonists inhibit proliferation and the production of IL-4 and/cr IFN-gamma in T helper l, T helper 2, and T helper 0 clones bearing the same TCR. J. Immunol., 158, 4065-4073.
11. DOWLING P., SHANG G., RAVAL S., MENONNA J., COOK S. and Husar W. (1996): Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J. Exp. Med., 184, 1513-1518.
12. D'SOUZA S. D., BONETTI B., BALASINGAM K. B., CASHMAN N. R., BARKER P. A., TROUTT A. B., RAINE C. S. and ANTEL J. P. (1996): Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J. Exp. Med., 184, 2361-2370.
13. + Th1 clones. Cell. Immunol., 163, 237-244.
14. FALCONE M. and BLOOM B. R. (1997): A T helper cell 2 (Th2) immune response against non-self antigens modifies the cytokine profile of autoimmune T cells and protects against experimental allergic encephalomyelitis. J. Exp. Med., 185, 901-907.
15. HAHN S., GEHRI R. and ERB P. (1995): Mechanism and biological significance of CD4-mediated cytotoxicity. Immunol. Rev., 146, 57-79.
16. + T helper type 2 and type 0 cells by T helper type 1 cells via Fas/Fas-ligand interaction. Eur. J. Immunol., 25, 2679-2685.
17. HANABUCHI S., KOYANAGI M., KAWASAKI A., SHINOHARA N., MATSUZAWA A., NISHIMURA Y., KOBAYASHI Y., YONEHARA S., YAGITA H. and OKUMURA K. (1994): Fas and its ligand in a general mechanism of T-cell-mediate cytotoxicity. Proc. Natl. Acad. Sci. USA, 91, 4930-4934.
18. HENKART P. A. (1994): Lymphocyte-mediated cytotoxicity: Two pathways and multiple effector molecules. Immunity, 1, 343-346.
19. ITOH N., YONEHARA S., ISHII A., YONEHARA M., MIZUSHIMA S., SAMESHIMA M., HASE A., SETO Y. and NAGATA S. (1991): The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell, 66, 223-243.
20. LAFAILLE J. J., VAN de KEERE F., HSU A. L., BARON J. L., HAAS W., RAINE C. S. and TONEGAWA S. (1997): Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J. Exp. Med., 186, 307-312.
21. + T lymphocytes. J. Immunol., 146, 3242-3249.
22. LYNCH D. H., RAMSDELL F. and ALDERSON M. R. (1995): Fas and FasL in the homeostatic regulation of immune responses. Immunol. Today, 16, 569-574.
23. MALIPIERO U., FREI K., SPANAUS K.-S., AGRESTI C., LASSMANN H., HAHNE M., TSCHOPP J., EUGSTER H.-P. and FONTANA A. (1997): Myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis is chronic/relapsing in perform knockout mice, but monophasic in Fas-and Fas ligand-deficient lpr and gld mice. Eur. J. Immunol., 27, 3151-3160.
24. MARTIN R. and MCFARLAND H. F. (1995): Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit. Rev. Clin. Lab. Sci., 32, 121-182.
25. NAGATA S. and GOLSTEIN P. (1995): The Fas death factor. Science, 267, 1449-1456.
26. NAGATA S. and SUDA T. (1995): Fas and Fas ligand: lpr and gld mutations. Immunol. Today, 16, 39-43.
27. + T-cell subsets in autoimmunity. Curr. Opin. Immunol., 9, 872-883.
28. OKUDA Y., BERNARD C. C. A., FUJIMURA H., YANAGIHARA T. and SAKODA S. (1998): Fas has a crucial role in the progression of experimental autoimmune encephalomyelitis. Mol. Immumol., 35, 317-326.
29. OLSSON T. (1995): Critical influences of the cytokine orchestration or the outcome of myelin antigen-specific autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol. Rev., 144, 245-268.
30. POWELL M. B., MITCHELL D., LEDERMAN J., BUCKMEIER J., ZAMVIL S. S., GRAHAM M., RUDDLE N. H. and STEINMAN L. (1990): Lymphotoxin and tumor necrosis factor-α production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. Int. Immunol., 2, 539-554.
31. RUDDLE N. H., BERGMAN C. M., MCGRATH K. M., LINGENHELD E. G., GRUNNET M. L., PADULA S. J. and CLARK R. B. (1990): An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med., 172, 1193-1200.
32. SABELKO K. A., KELLY K. A., NAHM M. H., CROSS A. H. and RUSSELL J. H. (1997): Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyelitis, but are not essential for immune privilege in the central nervous system. J. Immunol., 159, 3096-3099.
33. SABELKO-DOWNES K. A., CROSS A. H. and RUSSELL J. H. (1999): Dual role for Fas ligand in the initiation of and recovery from experimental allergic encephalomyelitis. J. Exp. Med., 189, 1195-1205.
34. SINGER G. G., CARRERA A. C., MARSHAK-ROTHSTEIN A., MARTÍNEZ C. and ABBAS A. K. (1994): Apoptosis, Fas and systemic autoimmunity: the MRL-lpr/lpr model. Curr. Opin. Immunol., 6, 913-920.
35. + cytotoxic T lymphocytes is due to fratricide. J. Immunol., 151, 658-667.
36. SUDA T., OKAZAKI T., NAITO Y., YOKOTA T., ARAI N., OZAKI S., NAKAO K. and NAGATA S. (1995): Expression of the Fas ligand in cells of T cell lineage. J. Immunol., 154, 3806-3813.
37. SUDA T., TAKAHASHI T., GOLSTEIN P. and NAGATA S. (1993): Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell, 75, 1169-1178.
38. SUVANNAVEJH G. C., DAL CANTO M. C., MATIS L. A. and MILLER S. D. (2000): Fas-mediated apoptosis in clinical remissions of relapsing experimental autoimmune encephalomyelitis. J. Clin. Invest., 105, 223-231.
39. TRAUTH B. C., KLAS C., PETERS A. M. J., MATZKU S., MOLLER P., FLAK W., DEBATIN K. M. and KRAMMER P. H. (1989): Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science, 245, 301-305.
40. WALDNER H., SOBEL R. A., HOWARD E. and KUCHROO V. K. (1997): Fas-and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis. J. Immunol., 159, 3100-3103.
41. WONG F. S., DITTEL B. N. and JANEWAY C. A. JR. (1999): Transgenes and knockout mutations in animal models of type 1 diabetes and multiple sclerosis. Immunol. Rev., 169, 93-100.
42. YONEHARA S., ISHII A. and YONEHARA M. (1989): A cell-killing monoclonal antibody (anti-fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med., 169, 1747-1756.